Cue Biopharma (CUE) vs Organogenesis (ORGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma (CUE) has outperformed Organogenesis (ORGO) over the past year, losing 0.2% versus a loss of 68.1%. Over five years, ORGO leads with a -87.9% price change compared with -94.0% for CUE. Organogenesis is the larger company by market cap ($169.9 million vs $163.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | ORGO |
|---|---|---|
| Share price | $22.51 | $1.32 |
| Market cap | $163.52M | $169.85M |
| 1-day change | -2.72% | -1.49% |
| YTD return | +146.01% | -74.52% |
| 1-year return | -0.22% | -68.12% |
| 5-year return | -94.04% | -87.95% |
| EPS (TTM) | $-28.75 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $7.08 |
| 52-week low | $4.98 | $1.28 |
| Distance from 52-week high | -50.53% | -81.35% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +290.94% | +51.52% |
| Average volume | 269.82K | 772.97K |
| Shares outstanding | 7.26M | 128.67M |
| Employees | 29 | 854 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed ORGO by 67.9 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Healthcare · Biotechnology · 29 employees
About Organogenesis
ORGO stock →Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Healthcare · Drug Manufacturers - Specialty & Generic · 854 employees
CUE vs ORGO FAQ
Which is bigger, Cue Biopharma or Organogenesis?
Organogenesis (ORGO) is larger, with a market capitalization of $169.85M compared with $163.52M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or ORGO?
CUE returned -0.22% over the past 12 months, compared with -68.12% for ORGO (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Organogenesis in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Cue Biopharma and Drug Manufacturers - Specialty & Generic for Organogenesis.